Forma To Rev Its Discovery Engine For Deubiquitination
This article was originally published in The Pink Sheet Daily
Executive Summary
In a new collaboration with Cancer Research Technology, drug-discovery firm Forma Therapeutics adds another area of cancer biology – and another unusual deal structure – to its panoply of partnerships.
You may also be interested in...
Celgene Returns To Forma’s Door, This Time With Option To Buy
The big biotech signed an expansive collaboration with the drug discovery company spanning multiple targets and numerous therapeutic areas. Celgene agreed to pay $225 million upfront and could eventually buy the company.
Deals of the Week: Is Botox On The Block?
A pair of setbacks have sent Allergan’s stock price south, but will a buyer take advantage and buy it in a mega-deal? Also, Amgen and Servier team up in a CV deal, Forma pursues an asset-focused strategy in tandem with Cancer Research Technology, and Immunocore reveals an antibody deal with GSK.
With Celgene Deal, Forma Makes First Foray Into Clinical Development
Forma Therapeutics has signed its largest and most ambitious oncology drug-discovery and development collaboration to date, in the exciting but early-stage area of protein homeostasis. Its new partner Celgene is no stranger to making big bets on promising cancer companies.